8 March 2016 - According to a recent US Government Accountability Office report, the Food and Drug Administration lacks complete, timely, accurate, and easily accessible postmarketing data to track potential safety issues of expedited drugs.

For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2499255&utm_source=Silverchair_Information_Systems&utm_campaign=Tuesday_March_8_2016&utm_content=eTOC&cmp=1&utm_medium=email